近期，凯莱英医药集团（天津）股份有限公司（以下简称"凯莱英"）接受了[X]等[X]家机构的调研，在 此次调研中，凯莱英披露了诸多关键信息，展现出公司在行业中的发展态势与潜力。 投资者活动关系类别为特定对象调研。时间方面，虽未明确具体日期，但从材料内容可推测为近期半年 报披露相关时段。地点未提及。参与单位名称为[X]等[X]家机构。上市公司接待人员姓名未在材料中体 现。 业绩概览 财务与展望 财务方面，2025H1营业收入31.88亿元，营业成本18.01亿元，毛利润13.87亿元 。在行业持续筑底背景 下，凯莱英预计2025全年收入实现13%-15%的增长 。公司将持续推进降本增效的相关管理措施，加大 市场开拓力度和业务竞争力提升，特别是多肽、寡核苷酸、偶联药物等增量业务，并以Sandwich Site为 依托，深化推进海外商业化产能建设。 声明：市场有风险，投资需谨慎。 本文为AI大模型基于第三方数据库自动发布，任何在本文出现的信 息（包括但不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成 个人投资建议。受限于第三方数据库质量等问题，我们无法对数据的真实性及完整性进行分辨或核 ...

Core Viewpoint - Bayer is committed to enhancing its focus and resource investment in China's innovation ecosystem, aiming to collaborate with local innovators to discover the next significant breakthroughs in drug development [1]. Group 1: Competition Announcement - Bayer China has officially launched the "Co-Creation New Drug" competition, inviting Chinese innovators and biotechnology companies to submit and showcase their innovative research pipelines, drug molecules, or new technologies with breakthrough potential [1]. Group 2: Target Therapeutic Areas - The competition focuses on several key therapeutic areas, including: - Precision Oncology - Precision Cardiorenal Diseases - Immunology & Inflammation [2]. Group 3: Research Pipeline Stages - The competition accepts submissions at various stages of the research pipeline, ranging from early pre-clinical candidate compounds (pre-PCC) to clinical proof of concept (clinical PoC) [2]. Group 4: Drug Molecule Forms - Eligible drug molecule forms include: - Biologics - Small molecules (SMOL) - Conjugated drugs (XDC) - Genetic medicine - Small nucleic acid drugs (siRNA) - Molecular glue - Other platform technologies [3]. Group 5: Evaluation Criteria - Submissions will be evaluated by a review committee composed of Bayer China's and global R&D and business development experts based on innovation level, key data, advancement speed, and alignment with Bayer's R&D strategy [4].